Revenue Remaining Performance Obligation

Name: MaxCyte Revenue Remaining Performance Obligation by Products & Services
Creator: OpenCapital
License: https://www.opencapital.sh/terms

MaxCyte·Products & Services·1 segment·Rolls up to Deferred Revenue

Breakdown

Segment	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Assay And Other Service Revenue	$364K	$240K	$415K	$645K
Total	$2.64M	$5.2M	$3.6M	$3.27M

Segments

Assay And Other Service RevenueView metric